Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MBOT Stock Forecast 2026-2027
$2.15
Current Price
$144.39M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MBOT Price Targets
+458.1%
To High Target of $12.00
+307.0%
To Median Target of $8.75
+155.8%
To Low Target of $5.50
MBOT Price Momentum
+0.9%
1 Week Change
+3.4%
1 Month Change
+31.1%
1 Year Change
+7.5%
Year-to-Date Change
-54.0%
From 52W High of $4.67
+72.0%
From 52W Low of $1.25
📊 TOP ANALYST CALLS
Did MBOT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Microbot Medical is one of their latest high-conviction picks.
Latest MBOT Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, MBOT has a bullish consensus with a median price target of $8.75 (ranging from $5.50 to $12.00). The overall analyst rating is N/A (N/A/10). Currently trading at $2.15, the median forecast implies a 307.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 458.1% upside. Conversely, the most conservative target is provided by Kyle Bauser at Roth Capital, suggesting a 155.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MBOT Analyst Ratings
2
Buy
0
Hold
0
Sell
MBOT Price Target Range
Low
$5.50
Average
$8.75
High
$12.00
Current: $2.15
Latest MBOT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MBOT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 3, 2025 | Roth Capital | Kyle Bauser | Buy | Initiates | $5.50 |
| Nov 28, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Oct 15, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Sep 11, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $12.00 |
| Apr 10, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $9.00 |
| Jan 24, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $9.00 |
| Jun 3, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Apr 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| Oct 18, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $8.00 |
| Jun 26, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $8.00 |
| Jun 6, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 9, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $8.00 |
| Nov 25, 2020 | Ladenburg Thalmann | Neutral | Downgrade | $N/A | |
| Nov 25, 2020 | H.C. Wainwright | Buy | Reiterates | $N/A | |
| Nov 25, 2020 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 18, 2020 | HC Wainwright & Co. | Buy | Maintains | $20.00 | |
| Jan 13, 2020 | H.C. Wainwright | Buy | Reiterates | $N/A | |
| Jan 13, 2020 | HC Wainwright & Co. | Buy | Reiterates | $26.00 | |
| Dec 24, 2019 | H.C. Wainwright | Buy | Reiterates | $N/A | |
| Dec 24, 2019 | HC Wainwright & Co. | Buy | Reiterates | $12.00 |
Microbot Medical Inc. (MBOT) Competitors
The following stocks are similar to Microbot Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MBOT
Microbot Medical
mkt cap
144.39M
Microbot Medical Inc. (MBOT) Financial Data
Microbot Medical Inc. has a market capitalization of $144.39M with a P/E ratio of -2.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -31.9%.
Valuation Metrics
Market Cap
$144.39M
Enterprise Value
$65.13M
P/E Ratio
-2.9x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+55.5%
Current Ratio
27.5x
Debt/Equity
1.1x
ROE
-31.9%
ROA
-20.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Microbot Medical Inc. (MBOT) Business Model
About Microbot Medical Inc.
What They Do
Develops innovative micro-robotic medical solutions.
Business Model
The company generates revenue by creating advanced medical devices that improve minimally invasive surgeries and procedures. By focusing on micro-robotics, it caters to the increasing demand for precision and less invasive treatment options in healthcare, positioning itself as a key player in the medical device market.
Additional Information
Headquartered in Massachusetts, Microbot Medical Inc. is at the forefront of technological advancements in surgical practices. Its pioneering work in robotic technology for endoluminal procedures addresses the healthcare industry's need for improved recovery times and procedural accuracy.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
20
CEO
Mr. Harel Gadot
Country
United States
IPO Year
1992
Website
microbotmedical.comMicrobot Medical Inc. (MBOT) Latest News & Analysis
Latest News
Quick Summary
Microbot Medical Inc. (Nasdaq: MBOT) reports positive customer feedback for its LIBERTY® System, with plans for a full market release in Q2 2026, following a successful limited market release.
Why It Matters
Positive customer feedback and market enthusiasm for Microbot Medical's LIBERTY® System suggest strong sales potential, which may lead to revenue growth and stock price appreciation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Microbot Medical Inc. announced that Emory University Hospital is the first to adopt its LIBERTY Endovascular Robotic System for patient care.
Why It Matters
Microbot Medical's LIBERTY system adoption by Emory University Hospital signals market validation, potential revenue growth, and increased investor confidence in its innovative technology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.
2 months ago
Quick Summary
Microbot Medical Inc. (Nasdaq: MBOT) has launched the LIBERTY® Endovascular Robotic System in the U.S. after hiring a commercial team and forming logistics partnerships, following positive feedback from healthcare professionals.
Why It Matters
Microbot Medical's LIBERTY® system's U.S. launch signals potential revenue growth and market validation, attracting attention from healthcare professionals and increasing investment interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Down 28.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Microbot Medical (MBOT)
2 months ago
Quick Summary
Microbot Medical (MBOT) is now technically oversold, suggesting reduced selling pressure. Analysts are raising earnings estimates, indicating a potential trend reversal.
Why It Matters
Microbot Medical being oversold suggests a rebound opportunity, while analysts' upgraded earnings forecasts signal potential growth, making it attractive for potential investment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The company will attend its first U.S. medical meeting after FDA clearance to engage potential users of the LIBERTY® System for commercial opportunities.
Why It Matters
The FDA clearance enables commercial engagement, potentially increasing market adoption of the LIBERTY® System, which could drive revenue growth and enhance investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A MedTech logistics provider will enhance inventory management and customer support as the company prepares to launch LIBERTY® in Q4 2023.
Why It Matters
The partnership enhances inventory management and customer support, crucial for a successful product launch, potentially boosting sales and investor confidence in the company's growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MBOT Stock
What is Microbot Medical Inc.'s (MBOT) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Microbot Medical Inc. (MBOT) has a median price target of $8.75. The highest price target is $12.00 and the lowest is $5.50.
Is MBOT stock a good investment in 2026?
According to current analyst ratings, MBOT has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.15. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MBOT stock?
Wall Street analysts predict MBOT stock could reach $8.75 in the next 12 months. This represents a 307.0% increase from the current price of $2.15. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Microbot Medical Inc.'s business model?
The company generates revenue by creating advanced medical devices that improve minimally invasive surgeries and procedures. By focusing on micro-robotics, it caters to the increasing demand for precision and less invasive treatment options in healthcare, positioning itself as a key player in the medical device market.
What is the highest forecasted price for MBOT Microbot Medical Inc.?
The highest price target for MBOT is $12.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 458.1% increase from the current price of $2.15.
What is the lowest forecasted price for MBOT Microbot Medical Inc.?
The lowest price target for MBOT is $5.50 from Kyle Bauser at Roth Capital, which represents a 155.8% increase from the current price of $2.15.
What is the overall MBOT consensus from analysts for Microbot Medical Inc.?
The overall analyst consensus for MBOT is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.75.
How accurate are MBOT stock price projections?
Stock price projections, including those for Microbot Medical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 18, 2026 3:55 PM UTC